Morgan Stanley raised the firm’s price target on Phibro Animal Health (PAHC) to $34 from $26 and keeps an Equal Weight rating on the shares. The firm said it is encouraged by the latest beat, and the company’s initial FY26 guidance is strong, pointing to a notably better profit profile into next year as it successfully integrates ZTS MFA business and compelling Phibro Forward initiatives. The shares should rise following the report, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health: Strong Q4 Performance Overshadowed by Growth and Profitability Challenges
- Phibro Animal Health sees FY26 EPS $2.52-$2.70, consensus $2.32
- Phibro Animal Health reports Q4 EPS 57c, consensus 52c
- PAHC Upcoming Earnings Report: What to Expect?
- Phibro Animal Health Declares Quarterly Cash Dividend